Mid Florida Hematology and Oncology Center — Orange City, Florida

Mid Florida Hematology and Oncology Center is a clinical research site located in Orange City, Florida, United States 32763.

Crixeo Clinical Trials Trust Score: 26/100 (FAILING). This profile has not yet been claimed by the site owner.

Mid Florida Hematology and Oncology Center has participated in 50 clinical trials with 34 currently active.

Therapeutic areas: Advanced Non-Small Cell Lung Cancer, Acute Myelogenous Leukemia, Multiple Myeloma.

Sponsors: Regeneron Pharmaceuticals, Notable Labs, Prelude Therapeutics.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Orange City

Browse all research sites in Florida · View every site in Orange City

Sponsor Feasibility Report

Trust Score: 26/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Mid Florida Hematology and Oncology Center?

Mid Florida Hematology and Oncology Center has a Crixeo Trust Score of 26/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Mid Florida Hematology and Oncology Center conducted?

Mid Florida Hematology and Oncology Center has 50 clinical trials on record, with 34 currently active. Their work covers Advanced Non-Small Cell Lung Cancer, Acute Myelogenous Leukemia, Multiple Myeloma.

Is Mid Florida Hematology and Oncology Center accredited by Crixeo Clinical Trials?

Mid Florida Hematology and Oncology Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Mid Florida Hematology and Oncology Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.